GSK, Relation Therapeutics Sign up to $110 Million AI Drug Discovery Deal

GSK in up to $110M drug discovery deal with Relation

GSK signs up to $110M AI drug discovery deal with Relation to build human cellular perturbation datasets and foundation models for new therapies. Read more here.

Relation unveils MORGAN, a cell model, plus a $110M GSK deal

The race to build an AI “foundation model of the cell” has a fuel problem. The biological data needed to train one is scarce, messy and inconsistent. Relation Therapeutics thinks the answer is to manufacture that data itself, and GSK is paying up to $110m to help. The London startup unveiled two things at once […] This story continues at The Next Web

GSK, Relation Therapeutics sign up to $110 million AI drug discovery deal

July 30 (Reuters) - British biotech firm Relation Therapeutics said on Wednesday it had ​entered into a ‌research collaboration with GSK worth up to $110 million to generate human cellular datasets and train ‌AI ​models for identifying ⁠potential new d...

Relation unveils MORGAN, the next-generation model of cellular biology

LONDON, July 30, 2026 (GLOBE NEWSWIRE) -- Relation today announced MORGAN (Multi-Omic Regulatory Genomics using Artificial Neural Networks), our flagship cellular foundation model...

Relation promises 'transformationally different success rates' in expanded AI pact with GSK

GSK is set to pay Relation Therapeutics up to $110 million to expand their existing partnership to use AI modeling for drug discovery. Under the Thursday deal, Relation will build a ...

Relation deepens GSK alliance with $110M deal - European Biotechnology Magazine

London-based Relation Therapeutics has expanded its research collaboration with GSK in an agreement worth up to $110 million (€97 million), as the AI biotech launches a foundation model designed to predict how human cells respond to experimental treatments. The post Relation deepens GSK alliance with $110M deal appeared first on European Biotechnology Magazine.